Clinical Trials Logo

Clinical Trial Summary

Aim of this trial is to assess the pharmacokinetics and pharmacodynamics (PK/PD) of recombinant human coagulation factor VIIa for injection (FⅦa) in patients with hemophilia.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04768699
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Lei Zhang, Doctor
Phone 13502118379
Email zhanglei1@ihcams.ac.cn
Status Recruiting
Phase Phase 1
Start date December 1, 2020
Completion date December 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT06320626 - Pharmacokinetic-guided Dosing of Emicizumab Phase 4
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Not yet recruiting NCT02554526 - Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors N/A
Completed NCT03818529 - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Active, not recruiting NCT03619863 - ATHN 7: Hemophilia Natural History Study
Recruiting NCT06010953 - SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment Phase 1/Phase 2
Completed NCT03951103 - rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A
Recruiting NCT05888870 - ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor Phase 4
Terminated NCT04303572 - The Hemophilia Inhibitor Eradication Trial Phase 3
Terminated NCT04489537 - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B Phase 3
Terminated NCT04548791 - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders Phase 1/Phase 2
Completed NCT06357572 - Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem
Recruiting NCT04647227 - SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors Phase 4
Completed NCT03372993 - Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
Terminated NCT03204539 - INdividualized ITI Based on Fviii(ATE) Protection by VWF Phase 4
Active, not recruiting NCT04205175 - A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab Phase 4
Recruiting NCT06312475 - Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors Phase 3
Recruiting NCT03598725 - Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China Phase 4
Completed NCT04723693 - An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families
Completed NCT04789954 - Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors Early Phase 1